Technology
Health
Biotechnology

Sophiris Bio

$1.13
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

$0.00 (0.00%) Pre-Market
$0.00 (0.00%) Pre-Market

Why Robinhood?

You can buy or sell Sophiris Bio and other stocks, options, ETFs, and crypto commission-free!

About

Sophiris Bio, Inc. Common Stock, also called Sophiris Bio, is a clinical-stage biopharmaceutical company, which engages in the development of products for the treatment of urological diseases. Read More The firm develops PRX302 as a treatment for the symptoms of benign prostatic hyperplasia which is a non cancerous enlargement of the prostate gland that causes a restriction in urine flow from the urethra resulting in lower urinary tract symptoms. The company was founded by James L. Heppell in May 2003 and is headquartered in La Jolla, CA.

Employees
6
Headquarters
La Jolla, California
Founded
2003
Market Cap
34.13M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
349.03K
High Today
$1.14
Low Today
$1.12
Open Price
$1.14
Volume
50.85K
52 Week High
$4.05
52 Week Low
$0.75

Collections

Technology
Health
Biotechnology
Medical
Biopharmaceutical
Pharmaceutical
2013 IPO
US

News

PR NewswireMar 13

Sophiris Bio Reports Fourth Quarter 2018 and Year-end Financial Results and Recent Corporate Highlights

SAN DIEGO and VANCOUVER, British Columbia, March 13, 2019 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company," "We" or "Sophiris"), a biopharmaceutical company developing topsalysin (PRX302), a first-in-class, pore-forming protein, in late-stage clinical trials for the treatment of patients with urological diseases, today reported financial results for the fourth quarter and full year 2018 and recent corporate highlights. "During the past year, Sophiris has made important progress in determinin...

174
Simply Wall StFeb 26

Some Sophiris Bio Shareholders Have Copped A Big 65% Share Price Drop

We think intelligent long term investing is the way to go. But unfortunately, some companies simply don’t succeed. For example, after five long years the Sophiris Bio, Inc. (FRA:BFF1) share price is a whole 65% lower. That is extremely sub-optimal, to say the least. We also note that the stock has performed poorly over the last year, with the share price down 44%. Furthermore, it’s down 42% in about a quarter, which is even more concerning. View our latest analysis for Sophiris Bio Sophiris Bio didn’t hav...

573

Earnings

-$0.20
-$0.16
-$0.13
-$0.09
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.12 per share
Actual
-$0.10 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.